Other Cancer News
Top Stories
Breast Cancer Drug Hope For Stomach Tumour Patients
POSTED: June 30, 2009Using the breast cancer drug Herceptin in patients with stomach cancer could help extend their lives by a quarter, new research has suggested. Adding Herceptin to standard chemotherapy treatment appears to prolong the lives of patients with advanced stomach cancer on average by nearly 2.7 months to 13.8 months - a 26 per cent increase in su...
Bladder Cancer No Longer A Death Sentence
POSTED: June 30, 2009SARASOTA, Fla. -- At 51, Charles Daniels had a lot to live for. A thriving construction business, a precious 11 year old daughter and a happy long-term relationship. When he was diagnosed with bladder cancer, he was determined to beat the odds. According to TMD, a medical tourism corporation, Daniels case is typical - he tried conventional medic...
Research Findings From National Cancer Institute Update Understanding Of Head And Neck Cancer
POSTED: June 30, 2009A report, 'Outpatient percutaneous endoscopic gastrostomy in selected head and neck cancer patients,' is newly published data in Surgical Endoscopy. "Percutaneous endoscopic gastrostomy (PEG) is a relatively simple and safe method of providing access for enteral feeding. The procedure is usually performed in hospitalized patients," investigators in Rio ...
Anal Cancer Isn't Being Caught Early: Doctors Lament Victims' Reluctance To Seek Checkups
POSTED: June 26, 2009If caught in time, anal cancer isn't typically deadly and doesn't require surgery. But a lack of awareness and a general reluctance to pay attention to symptoms in the anal area are fueling mortality rates, medical experts say. "Unfortunately, when we catch it, it is usually too late," said Dr. Vassiliki L. Tsikitis, a colorectal surgeon a...
An Effective Target Of Biological Therapy For Hepatocellular Carcinoma
POSTED: June 26, 2009It has been shown that constitutively activated STAT3 is detected in many HCC cell lines and tissues. This suggests that STAT3 is a promising molecular target for HCC gene therapy. RNA interference (RNAi) is a post-transcriptional gene-silencing mechanism, in which the homologous RNA sequences could be introduced into cells that inhibit the expression o...
Lung Cancer Alliance Issues Statement On FDA Tobacco Regulation Bill
POSTED: June 26, 2009Today, the U.S. House of Representatives overwhelmingly endorsed the U.S. Senate version of the FDA tobacco regulation bill with a 307-97 vote -- an emphatic exclamation point for the successful conclusion of a decade long battle. The final stop is the President's desk and a signing ceremony is expected to be held next week. Lung Cancer Alliance P...
Clarient Launches New Gene Mutation Test To Help Select Therapy For Non-Small Cell Lung Cancer
POSTED: June 26, 2009Clarient, Inc., a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, announced the launch of a new gene mutation test that can help physicians select the proper therapy for patients with non-small cell lung cancer (NSCLC). The test, called epidermal growth factor receptor (E...
Biomodels' Oral Mucositis Expertise Speeds FDA Approval For Actogenix's Phase 1b Trial Of AGO13 In Cancer Patients
POSTED: June 23, 2009WATERTOWN, Mass. -- Biomodels LLC, a preclinical research organization specializing in cancer support care, today announced that its customized research program allowed ActoGeniX NV, a development stage biopharmaceutical company, to rapidly attain Food and Drug Administration (FDA) approval for Phase 1b clinical trials of AGO13 in cancer patie...
Provectus Pharmaceuticals To Offer Compassionate Use Of PV-10 For Non-Visceral Indications In Cancer Patients
POSTED: June 23, 2009KNOXVILLE, Tenn. -- Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has begun a compassionate use program for PV-10 and has made the agent, which is in development as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients. Initially, the compassionate ...
ImmunoCellular Therapeutics Reports Additional Data From Promising Brain Cancer Clinical Trial
POSTED: June 23, 2009ImmunoCellular Therapeutics, Ltd., a biotechnology company, presented promising clinical data from a Phase I trial evaluating ICT-107, the company's dendritic cell-based cancer vaccine product candidate for the treatment of glioblastoma. These data were reported at the American Society of Clinical Oncology Meeting in Orlando, Florida (Abstract #2032), a...
